Fusobacterium nucleatum carcinogenesis and drug delivery interventions

Area of Science:

• Oncology
• Microbiology
• Immunology

Background:

• The tumor microbiome is increasingly recognized as a key factor in cancer development and treatment outcomes.
• Fusobacterium nucleatum (F. nucleatum) is implicated across diverse cancer types, including breast, colorectal, and lung cancers.
• Tumor-associated microbial communities are specific to cancer types and influence the tumor microenvironment.

Purpose of the Study:

• To comprehensively review the role of microbial communities, especially F. nucleatum, in tumor tissues.
• To explore the mechanisms by which these microbes affect tumor initiation, progression, and treatment response.
• To discuss potential therapeutic strategies, including vaccine development, targeting tumor-associated bacteria.

Main Methods:

• Literature review of studies investigating the tumor microbiome and F. nucleatum.
• Analysis of mechanistic data on microbial influence on cancer.
• Exploration of host immune responses to tumor-associated bacteria.

Main Results:

• F. nucleatum is prevalent in various tumors and impacts cancer progression.
• Tumor-associated microbiota directly influence tumor initiation, growth, and response to therapies like chemotherapy and immunotherapy.
• Eliminating tumor-associated F. nucleatum can trigger host immune responses against cancer cells.

Conclusions:

• The tumor microbiome, particularly F. nucleatum, plays a critical role in cancer.
• Understanding these microbial roles can lead to novel therapeutic strategies.
• Bacterial epitopes from F. nucleatum hold promise for developing anti-cancer vaccines.